Long-Term Follow-up of Allogeneic Bone Marrow Transplantation after Reduced-Intensity Conditioning in Patients with Chronic Myelogenous Leukemia in the Chronic Phase
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Although allogeneic transplantation is a curative therapy for chronic myelogenous leukemia (CML), treatment-related mortality is still a major cause of death after transplantation, especially in older patients. We investigated the safety and efficacy of reduced-intensity conditioning consisting of low-dose (600 cGy) total body irradiation and cytosine arabinoside (1 g/m2) together with a continuous infusion of granulocyte colony-stimulating factor and cyclophosphamide (120 mg/kg) in patients with CML in the chronic phase. Fractionated splenic irradiation (5 Gy) was also administered as part of the conditioning treatment. Eight patients older than 40 years underwent allogeneic bone marrow transplantation from an HLA-matched sibling following this conditioning. Regimen-related toxicities (equal to or greater than grade III) were not observed. Rapid restoration of 100% donor chimerism was confirmed by fluorescence in situ hybridization methods in 5 sex-mismatched transplant recipients. One patient died from severe acute graft-versus-host disease and another fromPneumocystis carinii pneumonia early in the course of transplantation. A sustained engraftment was achieved in 5 long-term survivors; in 1 case, the graft was rejected but the Philadelphia chromosome and BCR/ABL-negative autologous hemopoiesis were restored. After a minimum follow-up period of 60 months, 6 patients, including the patient with restored autologous hemopoiesis, were still alive and in remission with 100% donor chimerism. Six years after the transplantation, 1 patient experienced a cytogenetic relapse, which was successfully treated with donor lymphocyte infusions. In summary, this reduced-intensity conditioning resulted in a cure with markedly reduced regimen-related toxicities in this relatively older cohort of patients with CML.
- Thomas ED, Clift RA, Fefer A, et al. Marrow transplantation for the treatment of chronic myelogenous leukemia.Ann Intern Med. 1986;104:155–163.
- Rhee vanF, Szydlo RM, Hermans J, et al. Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.Bone Marrow Transplant. 1997;20:553–560. CrossRef
- Gratwohl A, Hermans J, Goldman JM. Risk assessment for patients with chronic myeloid leukemia before allogeneic blood or marrow transplantation.Lancet. 1998;352:1087–1092. CrossRef
- Brinker H. Population-based and sex-specific incidence rates in the 4 main types of leukemia.Scand J Haematol. 1982;29:241–249.
- Collins RH Jr, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.J Clin Oncol. 1997;15:433–444.
- Storb R, Yu C, Wagner JL, et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation.Blood. 1997;89:3048–3054.
- Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases.Blood. 1998;91:756–763.
- Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy.Blood. 1997;89:4531–4536.
- Khouri IF, Keating M, Korbling M, et al. Transplant-lite: induction of graft-versus malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies.J Clin Oncol. 1998;16: 2817–2824.
- Raiola AM, Lint Van MT, Lamparelli T, et al. Reduced intensity thiotepa-cyclophosphamide conditioning for allogeneic haemopoietic stem cell transplants (HSCT) in patients up to 60 years of age.Br J Haematol. 2000;109:716–721. CrossRef
- Takahashi S, Okamoto SI, Shirafuji N, et al. Recombinant human glycosylated granulocyte colony-stimulating factor (rhG-CSF)combined regimen for allogeneic bone marrow transplantation in refractory acute myeloid leukemia.Bone Marrow Transplant. 1994; 13:239–245.
- Kawasaki ES, Clark SS, Coyne MY, et al. Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro.Proc Natl Acad Sci U S A. 1988;85:5698–5702. CrossRef
- Stein C, Lange T, Ferencik S, Grosse-Wilde H, Henssge C. German population data of 3 tetrameric short tandem repeat lociD3S1744, D12S1090 and D18S849.Forensic Sci Int. 1998;91: 103–107. CrossRef
- Martinelli G,Trabetti E, Farabegoli P, et al. Early detection of bone marrow engraftment by amplification of hypervariable DNA regions.Haematologica. 1997;82:156–160.
- Dewald GW, Schad CR, Christensen ER, et al. Fluorescence in situ hybridization with X and Y chromosome probes for cytogenetic studies on bone marrow cells after opposite sex transplantation.Bone Marrow Transplant. 1993;12:149–154.
- Wakui M, Okamoto S, Ishida A, et al. Durable molecular remission in a patient with chronic myelogenous leukemia and host-derived hematopoiesis after allogeneic bone marrow transplantation.Bone Marrow Transplant. 1996;18:801–804.
- Fyles GM, Messner HA, Lockwood G, et al. Long-term results of bone marrow transplantation for patients with AML, ALL, and CML prepared with single dose total body irradiation of 500 cGy delivered with a high dose rate.Bone Marrow Transplant. 1991;8: 453–463.
- Khoury H, Adkins D, Brown R, et al. Low incidence of transplantation-related acute complications in patients with chronic myeloid leukemia undergoing allogeneic stem cell transplantation with a low-dose (550 cGy) total body irradiation conditioning regimen.Biol Blood Marrow Transplant. 2001;7:352–358. CrossRef
- Okamoto S, Takahashi S, Wakui M, et al. Treatment of advanced myelodysplastic syndrome with a regimen including recombinant human granulocyte colony-stimulating factor preceding allogeneic bone marrow transplantation.Br J Haematol. 1999;104:569–573. CrossRef
- Gratwohl A, Hermans J, van Biezen A, et al. Splenic irradiation before bone marrow transplantation for chronic myeloid leukemia.Br J Haematol. 1996;95:494–500. CrossRef
- Gratwohl A, Hermans J, van Biezen A, et al. No advantage for patients who receive splenic irradiation before bone marrow transplantation for chronic myeloid leukemia: results of a prospective randomized study.Bone Marrow Transplant. 1992;10:147–152.
- Sandmaier BM, Niederwieser D, McSweeney PA, et al. Induction of molecular remission in chronic myelogenous leukemia (CML) with nonmyeloablative HLA-identical sibling allografts [abstract].Blood. 2000;96:210a.
- Lalancette M, Rezvani K, Szydlo R, et al. Favorable outcome of non-myeloablative stem cell transplant (NMSCT) for chronic myeloid leukemia (CML) in first chronic phase: a retrospective study of the European Group for Blood and Marrow Transplantation [abstract].Blood. 2000;96:545a.
- Slavin S, Nagler A, Shapira M, et al. Non-myeloablative allogeneic stem cell transplantation for the treatment of patients with chronic myelogenous leukemia [abstract].Blood. 2000;96:203a.
- Aversa F, Tabilio A, Velardi A, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype.N Engl J Med. 1998;339: 1186–1193. CrossRef
- Reisner Y, Martelli MF. Bone marrow transplantation across HLA barriers by increasing the number of transplanted cells.Immunol Today. 1995;16:437–440. CrossRef
- Cutler C, Giri S, Jeyapalan S, Paniagua D, Viswanathan A, Antin JH. Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis.J Clin Oncol. 2001;19:3685–3691.
- Blaise D, Kuentz M, Fortanier C, et al. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Societe Fransaise de Greffe de Melle.J Clin Oncol. 2000;18: 537–546.
- Long-Term Follow-up of Allogeneic Bone Marrow Transplantation after Reduced-Intensity Conditioning in Patients with Chronic Myelogenous Leukemia in the Chronic Phase
International Journal of Hematology
Volume 75, Issue 5 , pp 493-498
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Allogeneic bone marrow transplantation
- Chronic myelogenous leukemia
- Reduced-intensity conditioning
- Long-term follow-up
- Industry Sectors
- Author Affiliations
- 1. Keio Bone Marrow Transplant Program, Division of Hematology, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582, Tokyo, Japan
- 2. Division of Hematology/Oncology, The Institute of Medical Science,The University of Tokyo, Tokyo, Japan